Advancing peptides for the treatment of rare endocrine and metabolic disorders
We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
Hypoparathyroidism is a rare endocrine disorder that is characterized by a deficiency in parathyroid hormone (PTH), resulting in dysregulation of calcium and phosphorus, two essential minerals in the body. Despite conventional treatments, patients frequently experience persistent life-altering symptoms and often develop secondary chronic conditions, such as kidney disease.
AZP-3601 is a parathyroid hormone (PTH) analog that targets a specific configuration of the PTH1 receptor to safely produce sustained levels of calcium in the blood and thereby control the symptoms of hypoparathyroidism. AZP-3601 has been designed to prevent chronic kidney disease by limiting the amount of calcium eliminated in the urine and to preserve bone integrity, an important benefit, since a large proportion of patients with hypoparathyroidism are middle-aged women often at an increased risk of developing osteoporosis.
We are preparing for the initiation of a Phase 1 program for AZP-3601 during the second half of 2020.
AZP-3404 is the first therapeutic peptide to leverage the biology of insulin-like growth factor binding protein 2 (IGFBP2) to stimulate multiple well-established pathways that restore the body’s regulation of fat and glucose metabolism.
At this time, we are generating additional data to prioritize potential target indications for AZP-3404. We are also conducting pre-investigational new drug activities in preparation for the initiation of a Phase 1 clinical trial in 2021.
Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.
Thierry Abribat, Ph.D.
Founder and Chief Executive Officer
Michael Culler, Ph.D.
Chief Scientific Officer
Soraya Allas, M.D., PH.D.
VP, Clinical Development and Regulatory Affairs
Patrick Loustau, M.S., M.A.
Chief Business Officer
Thomas Delale, Ph.D.
VP, Portfolio Management
Delphine Martinez, MBA
Board OF DIRECTORS
Chairman of the Board Directors, Amolyt Pharma
Felice Verduyn-van Weegen
Investment Manager at LSP
Partner at Novo Ventures
Managing Partner at Kurma Partners
Principal at OrbiMed
Partner at Pontifax
CEO of Amolyt Pharma
CSO of Amolyt Pharma
Managing Partner at LSP
Partner at Partners Healthcare Innovation Fund
Senior Investment Director at Bpifrance
Associate Director at Turenne Santé